HOME >> BIOLOGY >> NEWS
FDG-PET imaging clearly predicts lung cancer patients' response to chemotherapy

RESTON, Va. -- An earlier indication of whether chemotherapy benefits nonsmall cell lung cancer patientsprovided by positron emission tomography (PET) imagingcan guide doctors in offering them better care, according to researchers in the May Journal of Nuclear Medicine.

Our study demonstrates that patients who respond to chemotherapy can be identified early in the course of their treatment, and these patients will generally exhibit prolonged overall survival, explained Claude Nahmias, professor of radiology and medicine at the University of Tennessee Medical Center in Knoxville. Although we studied a relatively small number of patientsand our results should be interpreted with cautionit is clear that a repeat PET study with the radiotracer fluorodeoxyglucose (FDG) at the end of the first cycle of chemotherapy would allow the identification of those patients for whom the therapy was futile, he said. The ability to provide an early indication of therapeutic response has the potential to improve patient care by identifying those patients who do not benefit from their current treatment, explained Nahmias. Patients would benefit from either having chemotherapy and its associated toxic side effects stopped or going on to a different, and hopefully more adequate, therapeutic approach, added the co-author of Time Course of Early Response to Chemotherapy in NonSmall Cell Lung Cancer Patients With 18F-FDG PET/CT.

Nonsmall cell lung cancer is the most common type of lung cancer, usually growing and spreading more slowly than small cell lung cancer. Lung cancer is the second most common cancer and the most common cause of cancer-related death in both men and women in the United States. In 2007, about 213,380 new cases of lung cancer (both small cell and non-small cell) are expected in the United States, and about 160,390 people will die of this disease. For most patients with nonsmall cell lung cancer, current treatments do not cure the cancer.

'"/>

Contact: Maryann Verrillo
mverrillo@snm.org
703-652-6773
Society of Nuclear Medicine
9-May-2007


Page: 1 2

Related biology news :

1. New imaging method clarifies nutrient cycle
2. Methodist, University of Houston, Cornell combine biomedical imaging expertise
3. 2007 Image of the Year: Molecular imaging relates human brain chemistry to aggressive behavior
4. SNM advances professional definition for molecular imaging
5. Combining molecular imaging technologies to stop/prevent heart attacks
6. A first: Simultaneous PET/MR images of the brain debut, increase molecular imaging capabilities
7. Fusing imaging technologies creates synergy, helps diagnose heart disease accurately
8. Decoding gene expression in cancer tumors using noninvasive imaging
9. InfoSNM highlights advances in computer, information sciences for molecular imaging
10. Terahertz imaging goes the distance
11. New imaging approach promises insights into multiple sclerosis

Post Your Comments:
(Date:5/24/2013)... metastatic cancer , Cancer cells spread and grow ... Stimulation of the immune system can help to eliminate ... the immune system to ignore cancer cells. Regulatory T ... immune system response. In this issue of the ... Levy at Stanford University found that regulatory T cells ...
(Date:5/24/2013)... water scientists from around the world today issued a ... span of one or two generations, the majority of ... under the handicap of severe pressure on fresh water, ... no substitute. This handicap will be self-inflicted and is, ... to chronic underlying problems led by mismanagement and sent ...
(Date:5/23/2013)... Health at Emory University, along with partners at ... $4 million grant over four years to establish ... Exposome Research Center: Understanding Lifetime Exposures). The grant ... the United States. , The HERCULES Center ... Health Sciences (NIEHS) of the National Institutes of ...
Breaking Biology News(10 mins):JCI early table of contents for May 24, 2013 2JCI early table of contents for May 24, 2013 3JCI early table of contents for May 24, 2013 4JCI early table of contents for May 24, 2013 5JCI early table of contents for May 24, 2013 6JCI early table of contents for May 24, 2013 7JCI early table of contents for May 24, 2013 8A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 2A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 3A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 4Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3
(Date:5/23/2013)... , May 23, 2013 PuraMed BioScience ... and marketer of over-the-counter (OTC) medicinal and healthcare ... opinion on the company based on low market ... , Non-Prescription, All Natural Product to Treat Migraine ... Outperforms #1 Prescription Competitor , Currently Available ...
(Date:5/23/2013)... MA (PRWEB) May 23, 2013 ... inch wide and provide 15 mm travel range ... The small dimensions make these new positioners ... confined spaces. A vacuum rated version is also ... Drawings, specifications and datasheets can be found at: ...
(Date:5/23/2013)... , May 23, 2013 Virobay, Inc. today ... pain has reached an important milestone, as Virobay has ... - a selective cathepsin S inhibitor.   ... double-blind, randomized, placebo-controlled study designed to evaluate the safety, ... in healthy adults. "The initiation of this ...
(Date:5/23/2013)... 23, 2013 Z Trim Holdings, Inc. (OTC ... a variety of industries, announced that Chef ... at this year,s National Restaurant Association ("NRA") NRA Show, ... of the Research Chefs Association.  Chef Ryan spoke on ... the Bad and the Ugly," joining four other prestigious ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3
Cached News: